Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “abemaciclib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 11
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 11 pipeline programs matching "abemaciclib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

11 results for “abemaciclib” Back to intelligence hub

Search results

  1. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial
  2. Abemaciclib

    Eli Lilly and Company

    Breast Cancer

    phase 3 small molecule active

    1 trial
  3. Abemaciclib

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 3 small molecule active

    1 trial
  4. Abemaciclib

    Eli Lilly and Company

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  5. ABEMACICLIB , RO7197597

    Fondazione Telethon ETS

    ER-positive, HER2-negative Early breast cancer

    phase 2 small molecule active

    1 trial
  6. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial
  7. Abemaciclib

    Teva Pharma GmbH

    Triple Negative Breast Neoplasms

    phase 2 small molecule active

    1 trial
  8. Abemaciclib

    KAZIA THERAPEUTICS LTD

    CDK Gene Mutation

    phase 2 small molecule active

    1 trial
  9. MyDRUG (MMRC-085)

    Karyopharm Therapeutics Inc

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  10. Abemaciclib

    Eli Lilly and Company

    Breast Neoplasms

    approved small molecule completed

    1 trial
  11. Abemaciclib

    Eli Lilly and Company

    Metastatic Breast Cancer

    approved small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.